Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.
Sign Up to like & getrecommendations! Published in 2018 at "Current pharmaceutical design"
DOI: 10.2174/1381612825666190306162658
Abstract: BACKGROUND The use of single RAS-blockade is currently the recommended first-line treatment for proteinuric diabetic or non-diabetic nephropathy, as these agents were repeatedly shown in studies with hard renal outcomes to retard the progression of… read more here.
Keywords: renal outcomes; mineralocorticoid receptor; diabetic nephropathy; receptor antagonists ... See more keywords